secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeMD, Inc. (LFMD)
CIK:        0000948320
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001641172-25-008841
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeMD Q1 revenue up 49% to $65.7M; first GAAP profit; raises FY 2025 guidance
------------------------------------------------------------------------------

- Total revenue $65.7M (+49% YoY); telehealth revenue up 70% to $55.8M.
- GAAP net income $0.6M ($0.01 diluted EPS), first-ever positive GAAP EPS.
- Adj. EBITDA $8.7M (vs. $0.1M); telehealth adj. EBITDA $5.3M (vs. -$1.3M).
- FY 2025 guidance raised: revenue $268-275M, adj. EBITDA $31-33M.
- Partnered with LillyDirect/NovoCare for branded GLP-1 access (Zepbound, Wegovy).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/948320/000164117225008841/0001641172-25-008841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/948320/000164117225008841/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-008841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer